BH3-mimetics – the solution to chemoresistance?

References

• Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008; 111: 2977–2983
   PubMed Web of Science ®Google Scholar
• Diehl V, Stein H, Hummel M, Zollinger R, Connors J M. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology 2003; 2003: 225–247
   Google Scholar
• Kim H J, Hawke N, Baldwin A S. NF-[κ]B and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738–747
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Medeiros L J, Vassilakopoulos T P, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002; 100: 3935–3941
   PubMed Web of Science ®Google Scholar
• Smolewski P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res 2000; 6: 1150–1160
   PubMed Web of Science ®Google Scholar
• Willis S N, Chen L, Dewson G, et al. Pro-apoptotic Bak is sequestered by Mc1-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294–1305
   PubMed Web of Science ®Google Scholar
• Fletcher J I, Meusburger S, Hawkins C J, et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci USA 2008; 105: 18081–18087
   PubMed Web of Science ®Google Scholar
• Villunger A, Michalak E M, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 2003; 302: 1036–1038
   PubMed Web of Science ®Google Scholar
• Kim J Y, Ahn H J, Ryu J H, Suk K, Park J H. BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1α. J Exp Med 2004; 199: 113–124
   PubMed Web of Science ®Google Scholar
• Danial N N, Gramm C F, Scorrano L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424: 952–956
   PubMed Web of Science ®Google Scholar
• Willis S N, Fletcher J I, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856–859
   PubMed Web of Science ®Google Scholar
• Chen L, Willis S N, Wei A, et al. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393–403
   PubMed Web of Science ®Google Scholar
• Kuroda J, Puthalakath H, Cragg M S, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907–14912
   PubMed Web of Science ®Google Scholar
• Lindemann R K, Newbold A, Whitecross K F, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071–8076
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore S W, Shoemaker A R, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681
   PubMed Web of Science ®Google Scholar
• van Delft M F, Wei A H, Mason K D, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389–399
   PubMed Web of Science ®Google Scholar
• Mason K D, Vandenberg C J, Scott C L, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008; 105: 17961–17966
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375–388
   PubMed Web of Science ®Google Scholar
• Mason K D, Carpinelli M R, Fletcher J I, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173–1186
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker A R, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421–3428
   PubMed Web of Science ®Google Scholar
• Wilson W H, Czuczman M S, LaCasce A S, et al. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. J Clin Oncol 2008; 26, abstract 8511
   Web of Science ®Google Scholar
• Roberts A W, Brown J, Seymour J F, et al. An ongoing phase 1 study of ABT-263; pharmacokinetics, safety and anti-tumour activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2009; 129: 964–971
   Google Scholar
• Jayanthan A, Howard S C, Trippett T, et al. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma 2009; 50: 1174–1182
   PubMed Web of Science ®Google Scholar
• Huang S, Sinicrope F A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008; 68: 2944–2951
   PubMed Web of Science ®Google Scholar
• Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374–2380
   PubMed Web of Science ®Google Scholar
• Cragg M S, Kuroda J, Puthalakath H, Huang D CS, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires Bim and can be enhanced by BH3 mimetics. PLoS Med 2007; 4: 1681–1689
   PubMed Web of Science ®Google Scholar
• Witham J, Valenti M R, De-Haven-Brandon A K, et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007; 13: 7191–7198
   PubMed Web of Science ®Google Scholar
• Miller L A, Goldstein N B, Johannes W U, et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through noxa-dependent apoptosis. J Invest Dermatol 2009; 129: 964–971
   PubMed Web of Science ®Google Scholar
• Vogler M, Butterworth M, Majid A, et al. Concurrent upregulation of BCL-XL and BCL2A1 induces ∼1000 fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403–4413
   PubMed Web of Science ®Google Scholar
• Hallaert D Y, Jaspers A, van Noesel C J, van Oers M H, Kater A P, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008; 112: 5141–5149
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Garcia J F, et al. Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clin Cancer Res 2008; 14: 685–691
   PubMed Web of Science ®Google Scholar
• Sanchez-Aguilera A, Montalban C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006; 108: 662–668
   PubMed Web of Science ®Google Scholar
• Lock R, Carol H, Houghton P J, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1181–1189
   PubMed Web of Science ®Google Scholar